Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
AVTX Avalo Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: AVTX
Price (delayed)
$4.35
Market cap
$47.1M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.01
Enterprise value
-$78.01M
Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of
Highlights
AVTX's net income has soared by 151% YoY
The EPS has soared by 98% YoY and by 49% from the previous quarter
Avalo Therapeutics's gross margin has soared by 199% YoY but it has decreased by 10% from the previous quarter
AVTX's revenue has shrunk by 70% YoY
The company's gross profit fell by 10% QoQ and by 9% YoY
Key stats
What are the main financial stats of AVTX
Market
Valuations
Earnings
Shares outstanding
10.83M
Market cap
$47.1M
Enterprise value
-$78.01M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.38
Price to sales (P/S)
103.72
EV/EBIT
-1.12
EV/EBITDA
-1.11
EV/Sales
-176.89
Revenue
$441,000
Gross profit
$725,000
Operating income
-$50.42M
Net income
$73.01M
EBIT
$69.91M
EBITDA
$70.18M
Free cash flow
-$52.31M
Per share
Balance sheet
Liquidity
EPS
-$4.01
EPS diluted
-$16.43
Free cash flow per share
-$4.97
Book value per share
$11.49
Revenue per share
$0.04
TBVPS
$12.18
Total assets
$138.52M
Total liabilities
$15.91M
Debt
$0
Equity
$122.62M
Working capital
$121.33M
Debt to equity
0
Current ratio
22.61
Quick ratio
22.28
Net debt/EBITDA
-1.78
Margins
Efficiency
Dividend
EBITDA margin
15,913.4%
Gross margin
164.4%
Net margin
16,556%
Operating margin
-11,432.2%
Return on assets
58.9%
Return on equity
111%
Return on invested capital
N/A
Return on capital employed
52.6%
Return on sales
15,852.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AVTX stock price
How has the Avalo Therapeutics stock price performed over time
Intraday
-1.14%
1 week
21.17%
1 month
-13.69%
1 year
-60.45%
YTD
-41.45%
QTD
-45.69%
Financial performance
How have Avalo Therapeutics's revenue and profit performed over time
Revenue
$441,000
Gross profit
$725,000
Operating income
-$50.42M
Net income
$73.01M
Gross margin
164.4%
Net margin
16,556%
Avalo Therapeutics's gross margin has soared by 199% YoY but it has decreased by 10% from the previous quarter
AVTX's net income has soared by 151% YoY
AVTX's revenue has shrunk by 70% YoY
AVTX's operating income is up by 26% QoQ
Price vs fundamentals
How does AVTX's price correlate with its fundamentals
Growth
What is Avalo Therapeutics's growth rate over time
Valuation
What is Avalo Therapeutics stock price valuation
P/E
N/A
P/B
0.38
P/S
103.72
EV/EBIT
-1.12
EV/EBITDA
-1.11
EV/Sales
-176.89
The EPS has soared by 98% YoY and by 49% from the previous quarter
The equity has contracted by 8% from the previous quarter
The P/S is 195% higher than the 5-year quarterly average of 35.2 and 5% higher than the last 4 quarters average of 98.5
AVTX's revenue has shrunk by 70% YoY
Efficiency
How efficient is Avalo Therapeutics business performance
The ROE has soared by 122% since the previous quarter
Avalo Therapeutics's ROA has soared by 120% YoY
Dividends
What is AVTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AVTX.
Financial health
How did Avalo Therapeutics financials performed over time
AVTX's total liabilities has dropped by 93% year-on-year and by 10% since the previous quarter
Avalo Therapeutics's quick ratio has increased by 15% from the previous quarter
The debt is 100% smaller than the equity
The equity has contracted by 8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.